Acrux Ltd is primarily active in the pharmaceutical industry.

The main competitors of Acrux Ltd in the market are companies like Johnson & Johnson, Novartis AG, and GlaxoSmithKline Plc. These pharmaceutical giants also specialize in developing and marketing medical products, including topical dermatological treatments. As a renowned stock in the industry, Acrux Ltd faces stiff competition from these key players in the market.

Acrux Ltd is an Australian pharmaceutical company that specializes in developing and commercializing innovative dermatology products. Established in 1998, Acrux has grown to become a recognized leader in the transdermal drug delivery market. The company has achieved significant milestones, such as launching their first product, Axiron, in collaboration with global partners. Acrux's research and development efforts focus on creating effective treatments for various skin conditions and disorders. With a strong emphasis on innovation and quality, Acrux continues to strive for breakthrough advancements in the pharmaceutical industry.

Acrux Ltd has achieved several significant milestones throughout its history. Some notable achievements include the successful development and commercialization of innovative pharmaceutical products, collaborations with reputable partners, and regulatory approvals of key medications. The company's dedication to research and development has led to breakthroughs in dermatology, resulting in the launch of pioneering solutions for various skin conditions. Acrux Ltd's commitment to enhancing patient care and well-being truly sets them apart in the healthcare sector. Through their continuous efforts, Acrux Ltd has firmly established itself as a leading player in the pharmaceutical industry, consistently delivering impactful solutions to meet evolving market needs.

Acrux Ltd primarily operates in Australia, focusing on the development, manufacture, and commercialization of pharmaceutical products. With its headquarters located in West Melbourne, Acrux Ltd primarily serves the domestic market, catering to the healthcare needs of Australian consumers. The company's presence in Australia allows it to benefit from the country's robust healthcare sector and regulatory environment. By specializing in innovative and patient-friendly drug delivery technologies, Acrux Ltd aims to enhance treatment options for various medical conditions, demonstrating its commitment to improving healthcare outcomes for Australians.

Acrux Ltd is a renowned company that embodies a strong set of values and a robust corporate philosophy. By providing innovative solutions and exceptional products, Acrux Ltd aims to improve the lives of its customers. The company's commitment to excellence and customer satisfaction is evident in its continuous strive for quality and reliability. With a focus on research, development, and continuous improvement, Acrux Ltd maintains a leadership position in the industry. The company's values of integrity, transparency, and accountability underpin its business operations and foster long-lasting relationships with stakeholders. Acrux Ltd's corporate philosophy emphasizes sustainability, social responsibility, and ethical business practices, enabling it to make a positive impact in the industry and the wider community.

5 analysts currently rate the Acrux stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Acrux to generate revenue of 20,34 M AUD and earnings per share of 0,04 AUD.

Acrux Analītiķu cenu mērķi 2026

Converted at the current exchange rate, the Acrux share trades at 0,01 EUR (0,01 AUD).

The Acrux share (ACR.AX) is listed on 3 stock exchanges, including: Frankfurt (FJY.F), ASX (ACR.AX).

The company Acrux Ltd is an Australian company specializing in the development of pharmaceutical products. Acrux's business model includes various divisions, including research and development of new drugs, manufacturing and marketing of existing products, and licensing of technologies. One of Acrux's most well-known products is Axiron, a testosterone preparation in the form of a deodorant used to treat hypogonadism in men. Axiron is sold in over 35 countries worldwide and is one of the leading testosterone preparations on the market. Another important product of Acrux is Evamist, an estradiol spray used to treat menopausal symptoms in women. Evamist is also distributed worldwide and is known for its ease of use and effectiveness. Acrux pursues an open innovation strategy and collaborates with other companies to develop new technologies and products. For example, the company has an agreement with Poxel SA to develop a new diabetes medication. In addition, Acrux has a wide portfolio of technologies and know-how in the field of topical drug delivery. The company licenses these technologies and also works with other companies to incorporate them into new products. However, the pharmaceutical industry is highly competitive, which means that Acrux must regularly develop new products to remain competitive. For this reason, the company invests heavily in research and development and leverages its experience in topical administration to develop new products that meet the medical needs of patients. In summary, Acrux’s business model is focused on developing high-quality pharmaceutical products supported by innovative technologies and partnerships with other companies. Through investment in research and development and close collaboration with partners and customers, Acrux is able to develop innovative solutions and strengthen its position in the competitive market.

gaidāmā apgrozījums Acrux ir 20,34 M AUD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa Acrux ir 12,77 M AUD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

Acrux cenas un peļņas rādītājs (P/E) pašlaik ir 0,28. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Acrux akcijas vērtību.

Acrux cenas un apgrozījuma rādītājs (P/S) pašlaik ir 0,17. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Acrux akcijas vērtības mērs.

Acrux Eulerpool kvalitātes rādītājs ir 1/10.

Acrux ISIN ir AU000000ACR3. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

Acrux WKN ir A0B8LR. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

Acrux tikeris ir ACR.AX. Tikeris tiek izmantots Acrux akciju tirdzniecībai biržā.

Pēdējo 12 mēnešu laikā Acrux maksāja dividendes 0,09 AUD apmērā. Tas atbilst aptuveni 857,14 % dividendes ražībai. Nākamajos 12 mēnešos Acrux plāno maksāt dividendes 0,17 AUD apmērā.

Acrux pašreizējā dividendu rentabilitāte ir 857,14 %.

Acrux maksā dividendes, kas tiek sadalītas mēnešos , , , .

Acrux pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,17 AUD. Tas atbilst dividendes ražībai 1714,29 %.

Acrux tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Acrux apmērā 0,09 AUD, kas tika izmaksāta , tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija .

Pēdējās dividendes izmaksa notika .

Acrux dividendes tiek izmaksātas AUD.